Company Overview and News

 
RIU GoodOilConference Perth to open with financing perspective from Westpac’s Mark Beeley

2018-09-12 proactiveinvestors.com.au
RIU GoodOilConference Perth will deliver more good oil for the industry during day two of the event, as Westpac Banking Corp’s (ASX:WBC) (NZE:WBC) (FRA:WBC) (NYSE:WBK) Westpac Institutional Bank energy and resources director Mark Beeley opens with a talk on Financing Considerations.
FAR TEG SXA SSLZY SGC MEL LCK BAS ICN ROG BRNGF MUR ICNOF COPJF AGYYF FARYF COE WBC CUEYF NWE STRXD STO WEBNF STRXF ELXPF WBK CUE CUEYY AJQ WBC OIEXF EXR KEY OEX BRU

 
RIU GoodOilConference Perth opens with financing perspective from Westpac’s Mark Beeley

2018-09-12 proactiveinvestors.com.au
RIU GoodOilConference Perth will deliver more good oil for the industry during day two of the event, as Westpac Banking Corp’s (ASX:WBC) (NZE:WBC) (FRA:WBC) (NYSE:WBK) Westpac Institutional Bank energy and resources director Mark Beeley opens with a talk on Financing Considerations.
FAR TEG SXA SSLZY SGC MEL LCK BAS ICN ROG BRNGF MUR ICNOF COPJF AGYYF FARYF COE WBC CUEYF NWE STRXD STO WEBNF STRXF ELXPF WBK CUE CUEYY AJQ WBC OIEXF EXR KEY OEX BRU

 
RIU GoodOilConference Perth and WA Petroleum Day to put oil and gas players centre stage

2018-09-07 proactiveinvestors.com.au
The RIU GoodOilConference in Perth next week will focus on the current state of the oil and gas industry, and the explorers and producers operating in Australia.
FAR TEG HZN SXA SGC SRNLY LIO TAOIF BAS ICN BEPTF MUR COMRF CPTLY COPJF AGYYF NWE STRXD STRXF CUE ADX CTP EXR HZR BRU PCL CVN TAO SUR MEL LCK HZNFF ROG LIOEF BRNGF ICNOF FARYF COE CUEYF COI ADXRF ELXPF BCHEY CVONF CUEYY BPT AJQ RLE OIEXF CVX KEY OEX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:ICN / ICON ENERGY LIMITED on message board site Silicon Investor.

ICN.V ICN.V ICN.V ICNS ICNS ICNS
ICN Pharmaceuticals ICN Pharmaceuticals ICN Pharmaceuticals ICN Pharmaceuticals (ICN) ICN Pharmaceuticals (ICN) ICN Pharmaceuticals (ICN)
Get-together!!! Picnic-in-Pittsburgh Get-together!!! Picnic-in-Pittsburgh Get-together!!! Picnic-in-Pittsburgh Icon Industries ICN Icon Industries ICN Icon Industries ICN
ICNW ICNW ICNW 7/16/99 Jacobs, Farrill, Poticny u0026 LaForge Live Online 7/16/99 Jacobs, Farrill, Poticny u0026 LaForge Live Online 7/16/99 Jacobs, Farrill, Poticny u0026 LaForge Live Online
EcoTyre Tech. Icn. ETTIE EcoTyre Tech. Icn. ETTIE EcoTyre Tech. Icn. ETTIE Micrion Corp. (MICN) Micrion Corp. (MICN) Micrion Corp. (MICN)